Our pipeline represents the forefront of antiviral innovation. Grounded in the discovery of RdRp Thumb-1 as a novel, conserved viral target, we are developing transformative, broad-spectrum therapies designed to combat some of the world’s most pressing infectious diseases. Our lead candidate, MDL-001, is a first-in-class, orally administered antiviral targeting multiple high-burden viral pathogens.

Through rigorous science, bold innovation, and a commitment to global health, we are building a portfolio of best-in-class therapies that have the potential to protect billions of lives.